Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001783343 | SCV002024155 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2021-01-26 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001783343 | SCV003286673 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2023-06-14 | criteria provided, single submitter | clinical testing | Disruption of this splice site has been observed in individual(s) with mucopolysaccharidosis type IVA (PMID: 23876334, 34387910). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1322979). This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change affects an acceptor splice site in intron 3 of the GALNS gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GALNS are known to be pathogenic (PMID: 12442278). |
Fulgent Genetics, |
RCV001783343 | SCV005641501 | likely pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2024-04-19 | criteria provided, single submitter | clinical testing |